# Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

> **NCT02719613** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 67 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab
- **DRUG:** Dexamethasone
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Pomalidomide
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02719613
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-15
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-02-23
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719613, "Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02719613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*